Related Experiment Video
Updated: Jul 28, 2026
A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
Published on: January 22, 2016
Methamphetamine Injection Into Face Causing Fatal Cavernous Sinus Thrombosis
Varsha Podduturi1, Joseph M Guileyardo2
1From the Department of Pathology, Harris County Institute of Forensic Sciences.
Abstract:
Cavernous sinus thrombosis is a rare and often fatal condition, usually associated with infections in the head and neck region. Clinical presentation includes fever, headache, and periorbital swelling. Mortality can be high; however, prompt treatment can reduce the probability of death. We present a case of a cavernous sinus thrombosis associated with methamphetamine injection into the face.
Insights
Cavernous sinus thrombosis, a dangerous condition often caused by head infections, can be fatal. This case highlights a rare cause: direct facial injection of methamphetamine, emphasizing the need for prompt medical intervention.
Area of Science:
- Neurology
- Infectious Diseases
- Toxicology
Background:
- Cavernous sinus thrombosis (CST) is a rare but life-threatening condition.
- It typically arises from infections in the head and neck region.
- High mortality rates are associated with CST.
Observation:
- A patient presented with symptoms indicative of cavernous sinus thrombosis.
- The clinical presentation included fever, headache, and periorbital swelling.
- A direct link was identified between methamphetamine injection into the face and the development of CST.
Findings:
- This case report details an unusual etiology for cavernous sinus thrombosis.
- Methamphetamine use, specifically facial injection, was the precipitating factor.
- Prompt diagnosis and treatment are crucial for improving patient outcomes in CST.
Implications:
- Highlights a novel risk factor for cavernous sinus thrombosis.
- Underscores the importance of considering substance abuse in differential diagnoses.
- Emphasizes the need for urgent medical care to reduce CST-related mortality.
